Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
Melanie J. Davies, Peter van der Meer, Subodh Verma, Shachi Patel, Khaja Chinnakondepalli, Barry A Borlaug, Javed Butler, Dalane W Kitzman, Sanjiv J Shah, Signe Harring, Afshin Salsali, Søren Rasmussen, Dirk von Lewinski, Walter P. Abhayaratna, Mark C. Petrie, Mikhail Kosiborod
Topics & Concepts
MedicineHeart failureHeart failure with preserved ejection fractionEjection fractionInternal medicineCardiologySemaglutideObesityType 2 diabetesBaseline (sea)Diabetes mellitusEndocrinologyGeologyLiraglutideOceanographyDiabetes Treatment and ManagementCardiovascular Function and Risk FactorsHeart Failure Treatment and Management